Abstract
Abstract There is a need for blood biomarkers for meningioma. The role of circulating micro RNA in cancer diagnosis has been the objective of several studies. One of the extensively studied miRNA in different types of cancer is the microRNA-497 (miR-497). This study systematically evaluated miR-497 as a meningioma biomarker for disease diagnosis and classification. We studied exosomal and serum miR-497 in 74 meningioma samples (WHO grade I=25, WHO grade II=25, and WHO grade III=24), and 53 healthy controls. We also tested two different normalisers, endogenous and external, and evaluated their impact on the diagnostic value of miR-497. Another microRNA studied in meningioma is miR-219, which increased with increasing tumour grade. We combined miR-497 and miR-219 and estimated the sensitivity and specificity of the joint biomarkers to indicate meningioma grade and the relationship between miR-497 and miR-219 expression level and methylation class of meningioma. The serum and exosomal level of miR-497 distinguished meningioma from the control samples. Moreover, miR-497 was a suitable identifier for meningioma grade. When we combined miR-497 and miR-219, the efficacy of the combined biomarker was higher than miR-497 or miR-219 when used individually in meningioma classification. Both miR-497 and miR-219 showed a noticeable change with the methylation class of meningioma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
